Cited by 452BRCA gene mutations in cancerBreast Lesions and CarcinomasBreast Cancer Treatment Studies

The DOI matches its Crossref record; 28 of the 31 references it cites were found in a registry or an index.

Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1

Verhoog, LC, Brekelmans, CTM, Seynaeve, C, van den Bosch, LMC, Dahmen, G, van Geel, AN, Tilanus-Linthorst, MMA, Bartels, CCM, Wagner, A, van den Ouweland, A, Devilee, P, Meijers-Heijboer, EJ, Klijn, JGM·1998·The Lancet

DOI 10.1016/s0140-6736(97)07065-7

Open this paper in CoChat — free account

Abstract

Background Hereditary breast cancer has been associated with mutations in the BRCA1 and BRCA2 genes and has a natural history different from sporadic breast cancer. We investigated disease-free and overall survival for patients with a proven BRCA1 alteration.Methods We estimated disease-free and overall survival for 49 Dutch patients from 19 consecutive families with a proven specific BRCA1 mutation and one family with strong evidence for linkage to the BRCA1 gene. We compared clinical outcome and data on tumour size, histology, axillary nodal status, contralateral breast cancer, and oestrogen-receptor and progesterone-receptor status with those of 196 patients with sporadic breast cancer, matched for age and year of diagnosis.Findings Disease-free survival for BRCA1 and sporadic patients at 5 years was 49% (95% CI 33-64) and 51% (43-59), respectively (p=0.98). Overall survival at 5 years was 63% (47-76) and 69% (62-76), respectively (p=0.88). Recurrence and death rates did not differ significantly between groups. Hazard ratios for recurrence and death among BRCA1 patients were 1.00 (0.65-1.55) and 1.04 (0.63-1.71) relative to sporadic patients (p=0.88), and these did not differ significantly after adjustment for prognostic factors. Patients with BRCA1-associated breast cancer had twice as many progesterone-receptor-negative tumours (p<0.005) and development of contralateral breast cancer was four to five times as frequent as in the sporadic group (p<0.001).Interpretation We showed that disease-free and overall survival were similar for sporadic and hereditary breast cancer in the presence of different tumour characteristics, which has implications for screening prophylactic therapy, and different treatments of hereditary breast cancer.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(97)07065-7

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The Statistical Analysis of Failure Time Data.
Aitkin, M. A., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,875
A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1
Miki, Y., Swensen, J. J., Shattuck-Eidens, D. M., Futreal, P. A., Harshman, K., Tavtigian, S. V., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., et al. (1994) · Science · doi:10.1126/science.7545954 · Cited by 6,069
Linkage of Early-Onset Familial Breast Cancer to Chromosome 17q21
Hall, J., Lee, M. K., Newman, B. M., Morrow, J. E., Anderson, L. A., Huey, B., & King, M. (1990) · Science · doi:10.1126/science.2270482 · Cited by 2,544
Risks of cancer in BRCA1-mutation carriers
FORD, D. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91578-4 · Cited by 1,850
Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
Easton, D. F., Ford, D., & Bishop, D. T. (1995) · PubMed Central · Cited by 1,602
The statistical analysis of failure time data
Herson, J. (1981) · Controlled Clinical Trials · doi:10.1016/0197-2456(81)90009-x · Cited by 1,391
Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases
Stratton, M. R. (1997) · The Lancet · doi:10.1016/s0140-6736(96)10109-4 · Cited by 579
Age as prognostic factor in premenopausal breast carcinoma
de la Rochefordière, A., Campana, F., Fenton, J., Vilcoq, J. R., Fourquet, A., Asselain, B. J. R., Scholl, S. M., Pouillart, P., Durand, J., & Magdelénat, H. (1993) · The Lancet · doi:10.1016/0140-6736(93)92407-k · Cited by 481
BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients
Petrij-Bosch, A., Peelen, T., van Vliet, M., van Eijk, R., Olmer, R., Drüsedau, M., Hogervorst, F. B. L., Hageman, S., Arts, P. J. W., Ligtenberg, M. J. L., et al. (1997) · Nature Genetics · doi:10.1038/ng1197-341 · Cited by 432
Self-citation
Tumour biological features of BRCA1-induced breast and ovarian cancer
Johannsson, O. T., Idvall, I., Anderson, C., Borg, Å., Barkardottir, R. B., Egilsson, V., & Olsson, H. L. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)89007-7 · Cited by 344

Show all 31 references

Research works printed but not linked: 3

Lynch, 1993, Increased proliferation in hereditary breast cancer, Proc ASCO, 12, 82
Lynch, 1994, Distinctive clinicopathological features of BRCA1 linked hereditary breast cancer, Proc ASCO, 13, 56
Solin, 1996, Breast cancer in young women: the University of Pennsylvania experience—breast cancer: advances in biology and therapeutics, John Libbey Eurotext, 351

Sorted by citations

Items 301–400 of 450

Survival in Norwegian BRCA1 mutation carriers with breast cancer
Hagen, A. I., Tretli, S., Mæhle, L., Apold, J., Vedå, N., & Møller, P. (2009) · Hereditary Cancer in Clinical Practice · doi:10.1186/1897-4287-7-7
The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations
Armes, J. E., Egan, A. J. M., Southey, M. C., Dite, G. S., McCredie, M. R. E., Giles, G. G., Hopper, J. L., & Venter, D. J. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981201)83:11 · Cited by 260
Genetic risk and breast cancer survival: another link in the chain of evidence.
Burke, W., & Laya, M. (1999) · Journal of the National Cancer Institute · doi:10.1093/jnci/91.3.201 · Cited by 10
Prophylactic Mastectomy in Carriers ofBRCAMutations
Offit, K., Robson, M. E., & Schrag, D. (2001) · New England Journal of Medicine · doi:10.1056/nejm200111153452014 · Cited by 9
Prognostic and Predictive Factors and Targets for Therapy in Breast Cancer
Klijn, J. G. M., Berns, E. M. J. J., & Foekens, J. A. (2002) · CRC Press eBooks · doi:10.3109/9780203909249-7 · Cited by 9
Self-citation
ZDHHC3 as a Risk and Mortality Marker for Breast Cancer in African American Women
Kinney, N., Varghese, R. T., Anandakrishnan, R., & Garner, H. R. (2017) · Cancer Informatics · doi:10.1177/1176935117746644 · Cited by 8
BRCA-mutated Invasive Breast Carcinomas: Immunohistochemical Analysis of Insulin-like Growth Factor II mRNA-binding Protein (IMP3), Cytokeratin 8/18, and Cytokeratin 14
Mohanty, S. K., Lai, J., Gordon, O. K., Pradhan, D., Bose, S., & Dadmanesh, F. (2015) · The Breast Journal · doi:10.1111/tbj.12494 · Cited by 8
2–25 Risk Reduction of Contralateral Breast Cancer and Survival After Contralateral Prophylactic Mastectomy in BRCA1 or BRCA2 Mutation Carriers
Laronga, C. (2006) · Breast Diseases A Year Book Quarterly · doi:10.1016/s1043-321x(06)80436-4 · Cited by 8
Modified Radical Mastectomy and Total (Simple) Mastectomy
Bland, K. I., Chang, H. R., Prati, R., & Copeland, E. M. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-5221-0.00046-2 · Cited by 8
Expression and function of BRCA1 and BRCA2 in familial and sporadic breast cancer
Barnes (1999) · Histopathology · doi:10.1046/j.1365-2559.1999.00619.x · Cited by 8
Local Tumor Control and Survival
Schmidt‐Ullrich, R. (2000) · Surgical Oncology Clinics of North America · doi:10.1016/s1055-3207(18)30131-5 · Cited by 8
Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation
Frenel, J., Lusque, A., Delaloge, S., Ferrero, J.-M., Bachelot, T., Desmoulins, I., Lévy, C., Eymard, J. C., Gonçalvès, A., Patsouris, A., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02248-4 · Cited by 7
Large Genomic Rearrangement in BRCA1 and BRCA2 and Clinical Characteristics of Men with Breast Cancer in the United States
Tchou, J. C., Ward, M. R., Volpe, P., Palma, M. D., Medina, C. A., Sargen, M. R., Sonnad, S. S., Godwin, A. K., Daly, M. B., Winchester, D. J., et al. (2007) · Clinical Breast Cancer · doi:10.3816/cbc.2007.n.021 · Cited by 7
Impacto prognóstico da expressão imuno-histoquímica do BRCA1 nos carcinomas mamários esporádicos
Ribeiro‐Silva, A., Garcia, S. B., Chahud, F., & Zucoloto, S. (2005) · Jornal Brasileiro de Patologia e Medicina Laboratorial · doi:10.1590/s1676-24442005000300010 · Cited by 7
Genetische Risikofaktoren des Mammakarzinoms
Beckmann, M., Fasching, P. A., Gall, C. M., Bani, M., Brumm, C., & Krämer, S. (2002) · Der Gynäkologe · doi:10.1007/s00129-002-1193-5 · Cited by 7
A new germline mutation in BRCA1 gene in a sicilian family with ovarian cancer
Calò, V., Agnese, V., Gargano, G., Corsale, S., Gregorio, V., Cascio, S., Cammareri, P., Bruno, L., Augello, C., Gullo, A., et al. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-9049-z · Cited by 7
Prognostic and Predictive Factors and Targets for Therapy in Breast Cancer
Klijn, J. G. M., Berns, E. M. J. J., & Foekens, J. A. (2002) · CRC Press eBooks · doi:10.1201/b14039-5 · Cited by 7
Self-citation
Germline BRCA Mutation and Clinical Outcomes in Breast Cancer Patients Focusing on Survival and Failure Patterns: A Long-Term Follow-Up Study of Koreans
Kim, H., Choi, D. H., & Park, W. (2020) · Medicina · doi:10.3390/medicina56100514 · Cited by 5
Update Breast Cancer 2024 Part 2 – Patients with Early Stage Breast Cancer
Janni, W. J., Kolberg, H., Hartkopf, A. D., Fehm, T. N., Welslau, M., Müller, V., Schütz, F., Fasching, P. A., Jackisch, C., Marmé, F., et al. (2025) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-2533-2783 · Cited by 6
Impact of familial risk and mammography screening on prognostic indicators of breast disease among women from the Ontario site of the Breast Cancer Family Registry
Walker, M. J., Mirea, L., Cooper, K. L., Nabavi, M., Glendon, G., Andrulis, I. L., Knight, J. A., O’Malley, F. P., & Chiarelli, A. M. (2013) · Familial Cancer · doi:10.1007/s10689-013-9689-9 · Cited by 6
Hereditäre Karzinomsyndrome in der Frauenheilkunde
Beckmann, M. W., Kuschel, B., & Schmutzler, R. K. (1998) · Der Gynäkologe · doi:10.1007/pl00003100 · Cited by 6
Selecting for BRCA1 testing using a combination of homogeneous selection criteria and immunohistochemical characteristics of breast cancers
Miolo, G., Canzonieri, V., de Giacomi, C., Puppa, L. D., Dolcetti, R., Lombardi, D., Perin, T., Scalone, S., Veronesi, A., & Viel, A. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-360 · Cited by 6
Age at Onset of Bilateral Breast Cancer, the Presence of Hereditary BRCA1, BRCA2, CHEK2 Gene Mutations and Positive Family History of Cancer
Skasko, E., Kluska, A., Niwińska, A., Kwiatkowska, E., Bałabas, A., Piątkowska, M., Dąbrowska, M., Nowakowska, D., & Pieńkowski, T. (2009) · Oncology Research and Treatment · doi:10.1159/000200930 · Cited by 6
Local-regional control in breast cancer patients with a possible genetic predisposition.
Freedman, L., Buchholz, T., Thames, H. D., Strom, E., Mcneese, M., Hortobagyi, G., Singletary, S., Heaton, K., & Hunt, K. K. (2000) · International Journal of Radiation Oncology, Biology, Physics · doi:10.1016/s0360-3016(00)00761-6 · Cited by 6
The current social, political, and medical role of genetic testing in familial breast and ovarian carcinomas.
Weitzel, J. (1999) · Current Opinion in Obstetrics and Gynecology · doi:10.1097/00001703-199901000-00012 · Cited by 8
Immunohistochemical analyses of sporadic and familial (185delAG carriers) ovarian cancer in Israel.
Ravid, A., Barschack, I., Hirsh-Yechezkel, G., Goldberg, I., Bar-Sade, R., Chetrit, A., Reder, I., ben-Baruch, G., Gotlieb, W. H., Koplovic, J., et al. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00096-4 · Cited by 6
Inherited genetic predisposition in breast cancer
Rebbeck, T. R. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19991015)86:8+ · Cited by 5
The genetics of breast and ovarian cancer IV: a model of breast cancer progression
Lu, B., Macdonald, A. S., & Waters, H. R. (2010) · Scandinavian Actuarial Journal · doi:10.1080/03461238.2010.482188 · Cited by 5
Prognostic Impact of BRCA1 and BRCA2 Mutations on Long-Term Survival Outcomes in Egyptian Female Breast Cancer Patients
AbdelHamid, S. G., EL-Mesallamy, H. O., Abdel-Aziz, H., & Zekri, A. N. (2021) · Biology · doi:10.3390/biology10070566 · Cited by 5
Is Breast Conserving Surgery Efficacious in Breast Cancer Patients with BRCA1 or BRCA2 Germline Mutation?
Emiroğlu, S., Özkurt, E., Cabıoğlu, N., İğci, A., Saip, P. M., Yazıcı, H., Özmen, T., Özmen, V., Müslümanoğlu, M., & Tükenmez, M. (2023) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s395054 · Cited by 5
Educational Review: Role of the Surgeon in Hereditary Breast Cancer
Newman, L. A., Kuerer, H., Hunt, K. K., Vlastos, G., Ames, F., Ross, M. I., & Singletary, S. (2001) · Annals of Surgical Oncology · doi:10.1007/s10434-001-0368-y · Cited by 5
The Importance of Local Control in Early-Stage Breast Cancer: A Historical Review and a Discussion of Ongoing Issues
Morrogh, M., Borgen, P. I., & King, T. A. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9602-6 · Cited by 5
Laboratory identification of hereditary risk of breast and ovarian cancer.
Frank, T. S. (1999) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(99)80051-2 · Cited by 5
Cells-of-Origin of Breast Cancer and Intertumoral Heterogeneity
Joyce, R., & Visvader, J. E. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-70875-6_9 · Cited by 4
Breast Cancer Gene, BRCA1 and BRCA2
Choi, D. H. (2003) · Journal of Breast Cancer · doi:10.4048/jkbcs.2003.6.2.45 · Cited by 4
Breast Cancer Genetics
Lynch, H. T., Marcus, J. N., Lynch, J. A., Snyder, C., & Rubinstein, W. S. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-5221-0.00021-8 · Cited by 4
Breast Conserving Surgery: Optimizing Local Control in the Breast with the Assessment of Margins
Johnson, A. T., Henry‐Tillman, R., & Klimberg, V. S. (2001) · Breast Disease · doi:10.3233/bd-2001-12105 · Cited by 4
Genetic counseling of medullary breast cancer patients
Κroupis, C., Lianidou, E. S., Goutas, N. D., Vassilaros, S. D., Yannoukakos, D., & Petersen, M. B. (2004) · Clinical Genetics · doi:10.1111/j.1399-0004.2003.00231.x · Cited by 4
Prognostic factors for local recurrence following breast-conserving treatment in young women
Bollet, M. A., Kirova, Y., Fourquet, A., de Crémoux, P., & Reyal, F. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.67 · Cited by 4
Integrating Breast Cancer Genetics into Clinical Practice
Mukherjee, A., & Rakha, E. A. (2011) · Women s Health · doi:10.2217/whe.11.81 · Cited by 4
BRCA mutation in breast cancer patients: Prognostic impact and implications on clinical management
Loi, M., Desideri, I., Olmetto, E., Francolini, G., Greto, D., Bonomo, P., Simontacchi, G., Brina, L. D., Meattini, I., & Livi, L. (2018) · The Breast Journal · doi:10.1111/tbj.13100 · Cited by 4
Bases génétiques de la radiosensibilité des cancers du sein
Delaloge, S., & Marsiglia, H. R. (2005) · Cancer/Radiothérapie · doi:10.1016/j.canrad.2004.11.003 · Cited by 4
Hereditary Breast Cancer Syndromes: Molecular Pathogenesis and Diagnostics
Vos, S., van Diest, P. J., van der Wall, E., & van Diest, P. J. (2015) · Wiley eBooks · doi:10.1002/9780470015902.a0005375 · Cited by 4
Bilaterales Mammakarzinom und Lokalrezidiv: Prävalenz von BRCA-1- und BRCA-2-Genmutationen an einem unselektionierten Kollektiv
Bremer, M., Steinmann, D., Dörk, T., Börger, J., Rades, D., & Karstens, J. H. (2001) · Strahlentherapie und Onkologie · doi:10.1007/pl00002414 · Cited by 4
Inherited Risk of Women's Cancers: What's Changed for the Practicing Physician?
FRANK, T. S., & Critchfield, G. C. (2002) · Clinical Obstetrics & Gynecology · doi:10.1097/00003081-200209000-00011 · Cited by 4
14. BREAST CANCER PREVENTION
Salih, A. K., & Fentiman, I. (2002) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2002.tb11254.x · Cited by 4
Breast cancer detection among Irish BRCA1 & BRCA2 mutation carriers: a population-based study
Walsh, E. M., Farrell, M., Nolan, C., Gallagher, F., Clarke, R., McCaffrey, J., Kennedy, M. J., Barry, M., Kell, M., & Gallagher, D. (2016) · Irish Journal of Medical Science · doi:10.1007/s11845-015-1267-8 · Cited by 3
Korean Hereditary Breast Cancer
Kim, S. (2009) · Journal of Korean Medical Association · doi:10.5124/jkma.2009.52.10.952 · Cited by 3
The ubiquitin-mediated proteolytic pathway: Mode of action and clinical implications
Ciechanover, A. J., Orian, A., & Schwartz, A. L. (2000) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(2000)77:34+ · Cited by 281
The Genetics of Breast and Gynecologic Cancers
Wilbur, J. S., Rojan, A. A., & Legare, R. D. (2007) · Elsevier eBooks · doi:10.1016/b978-032303247-6.10003-6 · Cited by 3
Lymph node status as a prognostic factor in BRCA-positive breast cancer
Lee, J., Park, H. Y., Jung, J. H., Kim, W. W., Chae, Y. S., Lee, S. J., Lee, S., & Bae, Y. (2017) · Journal of Surgical Research · doi:10.1016/j.jss.2017.03.065 · Cited by 4
Gene screening and prevention of hereditary breast cancer
Klijn, J. G. M., & Meijers-Heijboer, H. E. J. (2003) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(03)00005-3 · Cited by 3
Self-citation
The Management of Women at High Risk of Experiencing Hereditary Breast and Ovarian Cancer
Hughes, K., Roche, C. A., Whitney, T. M., & Mclellan, R. (2000) · Disease Management & Health Outcomes · doi:10.2165/00115677-200007040-00004 · Cited by 4
Breast cancer screening: using familiality for earlier detection
Groenendijk, R. P., Rombouts, M. C., Ruers, T. J. M., Boetes, C., & Wobbes, T. (2002) · The Breast · doi:10.1054/brst.2001.0354 · Cited by 3
Clinical and pathological findings of BRCA1/2 associated breast cancer.
Pericay, C., Brunet, J., Díez, O., Sanz, J., Cortés, J., Baiget, M., & Alonso, C. (2001) · Breast · doi:10.1054/brst.2000.0185 · Cited by 3
Estrogen Receptors in BRCA1-Mutant Breast Cancer: Now You See Them, Now You Don't
Jordan, V. C. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm230 · Cited by 3
Clinical Implementation of Translational Genomics
Chung, W. K. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374934-5.00016-7 · Cited by 2
Young Breast Cancer Patients Undergoing Breast-Conserving Therapy: Role of BRCA1 and BRCA2
Bafford, A. C., Garber, J. E., Chittenden, A. B., & Golshan, M. A. (2008) · Springer eBooks · doi:10.1007/978-1-4020-8369-3_33 · Cited by 2
Surgical Management of High-Risk Patients
Rhei, E., Nixon, A. J., & Iglehart, J. D. (2001) · Breast Disease · doi:10.3233/bd-2001-12102 · Cited by 2
Management of the contralateral breast in patients with hereditary breast cancer
Eccles, D., & Evans, D. G. (2000) · The Breast · doi:10.1054/brst.2000.0143 · Cited by 2
Expression profiling of brca1 gene in familial breast cancer in India
Kulkarni, S. S. (2012) · AFRICAN JOURNAL OF BIOTECHNOLOGY · doi:10.5897/ajb12.078 · Cited by 2
Important Considerations for Recruiting Women to Cancer Genetics Studies in Puerto Rico
August, E. M., Quinn, G. P., Amorrortu, R. P., Closser, Z., Dutil, J., Puig, M., & Vadaparampil, S. T. (2011) · Journal of Cancer Education · doi:10.1007/s13187-011-0265-4 · Cited by 2
Effect of Prior Bilateral Oophorectomy on the Presentation of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers
Metcalfe, K. A., Foulkes, W. D., Lynch, H. T., Ghadirian, P., Tung, N., Olivotto, I. A., Warner, E., Olopade, O. I., Eisen, A. F., Weber, B., et al. (2005) · Hereditary Cancer in Clinical Practice · doi:10.1186/1897-4287-3-2-53 · Cited by 2
Truncation and Missing Family Links in Population-Based Registers
Leu, M. (2008) · Figshare · Cited by 2
Fas ligand expression in BRCA1-associated hereditary breast carcinoma clearly differs from that in sporadic breast carcinoma
Ito, Y., Noguchi, S., Takeda, T., & Matsuura, N. (2001) · Breast Cancer Research and Treatment · doi:10.1023/a:1010631020706 · Cited by 2
Molecular Genetic Analysis of Familial Breast Cancer in South Africa
Agenbag, G. (2005) · SUNScholar (Stellenbosch University) · Cited by 2
Androgen Receptor and Estrogen Receptors
Oosterkamp, H. M., & Bernards, R. (2002) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-1-59259-153-4_16 · Cited by 2
Article Commentary: Surgical Prophylaxis for Inheritable Malignant Diseases: Breast Cancer and Endocrine Disease
Benns, M. V., Luk, T., & Scoggins, C. R. (2009) · The American Surgeon · doi:10.1177/000313480907500701 · Cited by 2
Prophylactic Surgery and Inherited Cancer Predisposition
Hughes, K., Papa, M., Whitney, T. M., & Mclellan, R. (1999) · Springer eBooks · doi:10.1007/978-1-4615-4699-3_8 · Cited by 2
Breast cancer
Tobias, J. S., & Hochhauser, D. (2014) · Wiley eBooks · doi:10.1002/9781118468753.ch13 · Cited by 2
The Association Between Breast Cancer Predisposing Genetic Variants and Multifocal, Multicentric Breast Cancer
Vasigh, M., Mohamed, A., Jacobs, L. K., Lange, J. R., Camp, M. S., Sun, B., Wright, P., O’Donnell, M., Tran, H.-T., Sogunro, O. A., et al. (2024) · Annals of Surgical Oncology · doi:10.1245/s10434-024-16243-3 · Cited by 2
Treatment Patterns, Clinical Outcomes and Quality of Life in BRCA1/2-Associated Breast Cancer Patients: A Retrospective Analysis
Parger, A.-M., Gebhart, P., Muhr, D., Singer, C. F., & Tan, Y. Y. (2025) · Current Oncology · doi:10.3390/curroncol32050269 · Cited by 1
Carcinogenic form and characteristics of BRCA pathogenic variant breast cancer
Fujii, T. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02853-8 · Cited by 1
Prognostic and Predictive Assays in Invasive Breast Carcinoma Beyond Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2
Duckworth, L. A., & Hoda, R. S. (2025) · Surgical pathology clinics · doi:10.1016/j.path.2025.05.004 · Cited by 1
Germline BRCA testing in routine clinical practice: a single-center experience
Nikolényi, A., Dobi, Á., Sántha, D., Kószó, R., Iványi, M., Horváth, E., Enyedi, M. Z., Priskin, K., Csányi, B., Patócs, A., et al. (2026) · Pathology & Oncology Research · doi:10.3389/pore.2026.1612238 · Cited by 1
BRCA1 Cross-Talk with Hormone Receptors
Rosen, E. M., Ma, Y., & Fan, S. (2008) · Cancer treatment and research · doi:10.1007/978-0-387-09463-2_5 · Cited by 1
Management of Women with Inherited BRCA1 and BRCA2 Mutations
Swisher, E. M., & Calhoun, K. E. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0477-5_2 · Cited by 1
Towards Evidence-Based Management of Inherited Breast and Breast-Ovarian Cancer
Møller, P. (2004) · Hereditary Cancer in Clinical Practice · doi:10.1186/1897-4287-2-1-11 · Cited by 1
Predisposing genes in hereditary breast and ovarian cancer
Huusko, P. (1999) · Cited by 1
La chirurgie prophylactique du sein : perspectives médicale, individuelle, familiale et sociale
Eisinger, F., Julian-Reynier, C., & Sobol, H. (2001) · médecine/sciences · doi:10.4267/10608/1816
CLINICAL CASE: SYNCHRONOUS MALIGNANCY: LEFT BREAST AND OVARIAN CANCER ASSOCIATED WITH HEREDITARY BRCA1: 5382 INS C - MUTATION
Кравченко, О. В., Bashtan, O. P., Чорнобай, А. В., Mukovoz, O. E., & Hahal, O. V. (2023) · Bulletin of Problems Biology and Medicine · doi:10.29254/2077-4214-2023-2-169-244-251 · Cited by 1
CLINICOPATHOLOGICAL STUDY OF BREAST CANCER AND IMMUNOHISTOCHEMICAL EXPRESSION OF BRCA 1 AND BRCA2 – A PROSPECTIVE STUDY
Perugu, N. C., Komanapalli, S. K., Kuna, R., Chowdari, B., Devi, U., & Das, B. (2024) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2024.v17i1.48713 · Cited by 1
Genetic Alterations in HER2-Positive and Equivocal Breast Cancer by Immunohistochemistry
Tsai, Y., Hsu, C., Chiu, Y.-N., Huang, C., Chou, S.-H., Lin, Y., Chao, T., Liu, C., Chiu, J., & Tseng, L. (2025) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s507189 · Cited by 1
Características clinicopatológicas y evolución clínica de pacientes con cáncer de mama y mutaciones en los genes BRCA1 o BRCA2
Pericay, C., Díez, O., Campos, B., Balmañ, J., Domènech, M., Lerma, E., Baena, M., Sabaté, J., Gómez, A., López, J., et al. (2001) · Medicina Clínica · doi:10.1016/s0025-7753(01)72050-7 · Cited by 1
Invasive bilateral breast cancer and high grade serous ovarian cancer with BRCA1-germline mutation and brainstem metastasis under PARP inhibitors
Zahari, M. M., Chiorean, A. R., Duma, M. M., Ungureanu, A., & Kacsó, G. (2019) · Archive of Clinical Cases · doi:10.22551/2019.24.0603.10156 · Cited by 1
Impact of MRI Screening on High-Risk Patient Outcome
Podo, F., Warner, E., Santoro, F., & Sardanelli, F. (2020) · Springer eBooks · doi:10.1007/978-3-030-41207-4_13 · Cited by 1
Some new actuarial models of the insurance implications of genetic testing for breast and ovarian cancer
Lu, B. (2007) · Cited by 1
The breast
Pfeifer, J. D., & Wick, M. R. (2015) · Cambridge University Press eBooks · doi:10.1017/9781139137201.011 · Cited by 1
Hereditary breast cancer
Lazarev, A. F., Zadontseva, N. S., & Gofman, A. A. (2014) · Russian Journal of Oncology · doi:10.17816/onco40062 · Cited by 1
Microarray Bioinformatics and Applications in Oncology
Peeters, J. K. (2008) · EUR Research Repository (Erasmus University Rotterdam) · Cited by 1
CE Forum
Cain, S. (2000) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.2000.tb00277.x · Cited by 1
Breast conservation in BRCA1 or BRCA2 mutation carriers with early stage breast cancer
Phillips, K. A., & McKay, M. J. (2001) · Australasian Radiology · doi:10.1046/j.1440-1673.2001.00903.x · Cited by 1
Contralateral mastectomy for women with hereditary breast cancer
Michels, K. B. (2014) · BMJ · doi:10.1136/bmj.g1379 · Cited by 1
Recurrent Early-Stage Triple-Negative Breast Cancer
Adonizio, C. S., Granà, G., Sharan, K. P., Rose, L. J., Zibelli, A. M., Miller-Samuel, S., & Morris, G. J. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.09.012 · Cited by 1
Assessing Genetic Risk of Cancer
Acton, R. T., & Nabell, L. M. (2004) · Springer eBooks · doi:10.1007/0-387-21596-4_1 · Cited by 1
Breast Cancer
Souhami, R., & Tobias, J. S. (2005) · doi:10.1002/9780470994887.ch13 · Cited by 1
Molekulare Diagnostik
Kommoss, F. K. F., & Ridder, R. (2002) · Steinkopff eBooks · doi:10.1007/978-3-642-57533-4_16 · Cited by 1
Präventives Versorgungskonzept bei erblichem Brustkrebs
Rhiem, K., & Schmutzler, R. K. (2009) · Springer eBooks · doi:10.1007/978-3-540-73042-2_47
Synthetic Sickness with Molecularly Targeted Agents Against the EGFR Pathway
Stanley, J. A., & Yang, E. S.-H. (2015) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-14151-0_16
Screening and Clinical Implications for BRCA1 and BRCA2 Mutation Carriers
Plon, S. (1998) · Journal of mammary gland biology and neoplasia · doi:10.1023/a:1018731914813

Authors: Verhoog, L., Brekelmans, C., Seynaeve, C., van den Bosch, L., Dahmen, G., van Geel, A., Tilanus-Linthorst, M., Bartels, C., Wagner, A., van den Ouweland, A., Devilee, P., Meijers-Heijboer, E., & Klijn, J.
Affiliations: Academisch Ziekenhuis Rotterdam (NL)
Erasmus University Rotterdam (NL)
Leiden University (NL)
Corresponding author: Klijn, JGM
ORCID: Wagner, A
Devilee, P
Venue: The Lancet
Publisher: Elsevier BV
Published: 1998-01
Volume: 351
Issue: 9099
Pages: 316-321
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(97)07065-7
OpenAlex: W2137086763
Cited by: 452
References: 31
Citations by year: 2026: 3 · 2025: 8 · 2024: 3 · 2023: 7 · 2022: 1 · 2021: 7 · 2020: 8 · 2019: 7 · 2018: 4 · 2017: 5 · 2016: 4 · 2015: 13 · 2014: 10 · 2013: 7 · 2012: 5
FWCI: 28.46
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
Pure Amsterdam UMC (submittedVersion)
Funders: KWF Kankerbestrijding
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords: hereditary breast cancer, BRCA1 mutation, sporadic breast cancer, disease-free survival, overall survival, contralateral breast cancer, estrogen receptor status, tumor characteristics, tumor recurrence, breast cancer screening
MeSH terms: Adult, Aged, Breast Neoplasms, Female, Humans, Middle Aged, Prognosis, Risk, Odds Ratio, Survival Analysis, Germ-Line Mutation, Disease-Free Survival, Genes, BRCA1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks